natgillin/translations-raw huggingface dataset:
The process according to claim 10, wherein the calcium carbonate is first contacted with the at least one acid having a pKa of less than or equal to 2.5 and after 5 % of the total amount of the at least one acid having a pKa of less than or equal to 2.5 have been added, the calcium carbonate is contacted with the at least one water soluble non-polymeric organic and/or inorganic weak acid and/or hydrogen salt of said at least one water soluble non-polymeric organic and/or inorganic weak acid. 
Postupak prema zahtjevu 10, naznačen time da se kalcijev karbonat prvo dovodi u kontakt sa najmanje jednom kiselinom koja ima pK, od manje od ili jednako 2.5 i nakon što je dodano 5 % ukupne količine najmanje jedne kiseline koja ima pK, od manje od ili jednako 2.5, kalcijev karbonat se dovodi u kontakt sa barem jednom u vodi topivom ne-polimernom organskom i/ili anorganskom slabom kiselinom i/ili vodikovom soli navedene barem jedne u vodi topive ne-polimerne organske i/ili anorganske slabe kiseline.
to 700 mmol per litre ascorbate anion provided by ascorbic acid, one or more salts of ascorbic acid, or a mixture thereof; 
do 2000 mmol po litri askorbatnog aniona osiguranog putem askorbinske kiseline, jedne ili više soli askorbinske kiseline, ili njihove smjese; i
a third outer layer (13, 113,213) which is substantially hydrophilic and is suitable for permeation of vapor-phase perspiration, for absorbing liquid-phase perspiration that arrives from the first layer (11, 111, 211, 411), and for distributing said liquid-phase perspiration over a large surface thereof so that it can evaporate outwardly, 
- - trećeg vanjskog sloja (13, 113, 213), koji je u biti hidrofilan i pogodan je za propuštanje znoja u parovitom stanju, za apsorpciju tekuće faze znoja koji dolazi iz prvog sloja (11, 111, 211, 411) 1 za raspodjelu navedene tekuće faze znoja na velikoj površini tako da se može ispariti prema van,
The abovementioned steps are, of course, best automated and various testing stages or steps can be included in the process. 
Gore navedeni stupnjevi se naravno mogu na najbolji način automatizirati i u cijelom procesu mogu biti uključeni različiti stupnjevi ispitivanja.
This can be removed in a conventional manner using zinc and either formic or acetic acid. 
Ova se može odvojiti na konvencionalan način korištenjem cinka i ili mravlje ili octene kiseline.
In some embodiments, the recombinant CMV vector encodes an antigen from a virus. The viruses may include but are not limited to Influenza virus, West nile virus, Poliovirus, SIV, HIV, HCMV, Kaposi's sarcoma associated herpesvirus, Ebola virus, Chikungunya virus, Dengue virus, Monkeypox virus, varcella zoster virus, Epstein-barr virus, Herpes simplex 1 virus and Herpes simplex 2 virus. 
Rekombinantni vektor RhCMY ili HCMY ili pripravak u skladu s patentnim zahtjevom 13, naznačen time što zaraznu bolest uzrokuje virus humane imunodeficijencije (HIV), virus majmunske imunodeficijencije (SIV), ljudski citomegalovirus (HCMV), hepatitis C, papilomavirus, plazmodij, herpesvirus povezan s Kaposijevim sarkomom, virus varicela-zoster, virus ebole, Mycobacterium tuberculosis, virus Chikungunya, virus denge, virus majmunskih boginja, herpes simpleks 1, herpes simpleks 2, Epstein-Barrov virus (EBV), poliovirus, virus influence ili Clostridium tetani.
Nicotine-containing product according to one of claims 1 to 5, characterized in that it comprises 10-15 wt% of nicotine or the pharmaceutically acceptable nicotine salt. 
Proizvod koji sadrži nikotin u skladu s patentnim zahtjevom 9, naznačen time što sadrži manje od 20%, težinski, nikotina ili farmaceutski prihvatljivog derivata nikotina, po mogućnaosti 8-18%, težinski, a najpoželjnije 10-15%, težinski.
represents hydrogen atom or C1-4 alkyl group; and, where appropriate, separating the enantiomers and/or diiastereomers, and/or cis- and/or trans- isomers of compounds of formula (I), or intermediates thereto, by conventional methods, and optionally thereafter forming salts and/or hydrates and/or solvates of the compound of formula (I). 
R? predstavlja vodikov atom ili C,.4 alkil skupinu; i, gdje je prikladno, odvajanje enantiomera i/ili dijastereomera, i/ili cis- i/ili trans-izomera spojeva formule (T), ili njihovih intermedijera, konvencionalnim postupcima, te nakon toga, opcijski, oblikovanje soli i/ili hidrata i/ili solvata spoja formulo (1).
In particular, in one aspect a method of treating a rheumatic disease in a patient is provided comprising a step (a) of administering an agent capable of activating CD4+CD25+ regulatory T cells and a step (b) of administering methotrexate, wherein step (a) and step (b) can be conducted simultaneously, separately or sequentially and in either order. 
Sredstvo koje može aktivirati regulacijske T-stanice CD4+CD25+ i namijenjeno je upotrebi u liječenju reumatske bolesti kod pacijenta, gdje se pacijent liječi metotreksatom, naznačen time što je sredstvo humanizirano protutijelo protiv CD4 koje sadrži V domenu lanca H i V domenu lanca L, te što:
The resulting juice that is located within the space 1002 may be decanted from the container without removing the lid through the openings. 
Nastali sok koji se nalazi u prostoru 1002 se može izliti iz posude bez uklanjanja poklopca kroz otvore.
is selected from the group consisting of -O- and -S-; 
se L2 odabire iz skupine koju sačinjavaju -O- i -S-;
In preferred embodiments, the BC loop of the anti-myostatin Adnectin of the invention comprises an amino acid sequence selected from the group consisting of: SWSLPHAGHVN, (SEQ ID NO: 7) 
leucin na položaju 4 u petlji BC (SEQ ID NO: 34) je zamijenjen aminokiselinom koju se bira iz skupine koju čine M i V;
adding to the aqueous preparation one or more aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in an amount such that the total amount of aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in the aqueous preparation is from 250 ppm to 5000 ppm, calculated relative to the water in the preparation; 
(a) dodavanje u vodeni pripravak jednog ili više biocida koji oslobađaju aldehid i/ili biocida s jednom ili više aldehidnih skupina u količini tako da je ukupna količina biocida koji oslobađaju aldehid i/ili biocida s jednom ili više aldehidnih skupina u vodenom pripravku od 250 ppm do 5000 ppm, izračunato u odnosu na vodu u pripravku;
The pyridine derivative or the pharmaceutically acceptable salt thereof, or the solvate thereof according to claim 14, wherein Z is Z1, and R6 and R7 are, on a phenyl ring, chlorine substituents at 2- and 5-positions, chlorine substituents at 3- and 5-positions, methyl substituents at 2- and 5-positions, trifluoromethyl substituents at 2- and 5-postions, or chlorine and methyl substituents at 2- and 5-positions, respectively; 
Derivat piridina ili njegova farmaceutski prihvatljiva sol, ili njegov solvat prema zahtjevu 12, naznačen time da Z je Z1, 1 R 1 Ri su, na fenilnom prstenu, klorovi supstituenti na 2- i 5-položaju, klorovi supstituenti na 3- i 5- položaju, metilni supstituenti na 2- i 5-položaju, trifluorometil supstituenti na 2- i 5-položaju, ili odgovarajući klorovi i metilni supstituenti na 2- i 5-položaju;
several thermally conductive heat exchange fins (78, 79; 80, 81) are attached in a thermally conductive manner at variable radiuses around both ends of the rotation axis situated inside the outer shell (Os). 
u cilju bolje razmjene topline, oko oba kraja centralne osi rotacije koja prolazi kroz vanjsko kućište (SK) postavljena su orebrenja (78, 79, 80, 81), pri čemu su spomenuta orebrenja postavljena na različitim udaljenostima od osi rotacije 1 fiksirana na način koji omogućuje provođenje topline.
The method of claim 1, the method further comprising a size exclusion chromatography. 
Metoda iz bilo kojeg od patentnih zahtjeva 1 do 6, metoda nadalje obuhvaća kromatografiju isključenjem prema veličini.
wherein Ar1, Ar2, A and R1-R10 are as defined in claim 1, comprising the steps of: adding to a thiolactone of the following formula VIII more than 1 equivalent of a Grignard reagent of the following formula IX to obtain a compound V; 
naznačen time da su Ar', Ar', A i R'-R'" kako je definirano u zahtjevu 1, te sadrži korake: dodavanja u tiolakton slijedeće formule VIII više od 1 ekvivalenta Grignardovog reagensa slijedeće formula IX da se dobije spoj V; redukciju spoja V; te ako se želi, deprotekcije dobivenog spoja, u skladu sa slijedećom shemom:
an antisense oligomer which consists of a nucleotide sequence having deletion, substitution, insertion and/or addition of 1 to 3 nucleotides in the nucleotide sequence of SEQ ID NO: 1 or 2, and has an activity to cause skipping of the 51st exon in the human dystrophin gene; 
antisensni oligomer sastavljen od nukleotidne sekvence koja ima deleciju, supstituciju, inserciju i/ili adiciju od 1 do 3 nukleotida u nukleotidnoj sekvenci SEQ ID NO: 1 ili 2, i ima aktivnost izazvati preskakanje 51-vog egzona u humanom distrofinskom genu; i
An antibody or FcRn-binding fragment thereof as defined in any one of claims 1 to 10 or a composition as defined in claim 16 or 17, for use in the treatment of an autoimmune disease, such as myasthenia gravis, Pemphigus vulgaris, Neuromyelitis optica, Guillain-Barré syndrome, lupus, and thrombotic thrombocytopenic purpura. 
Antitijelo ili njegov fragment koji se vezuje za FcRn kako je definirano u bilo kojem patentnom zahtjevu od 1 do 10 ili pripravak kako je definirano u patentnom zahtjevu 16 ili 17, za primjenu u liječenju autoimune bolesti, kao što je miastenija gravis, obični pemfigus, optički neuromijelitis, Guillan-Barreov sindrom, lupus i trombotična trombocitopenična purpura.
The dosage form of claim 14, wherein the lipase activity of the dosage form is from about 500 to about 5,000 USP units, preferably from about 675 to about 825 USP units; more preferably wherein the lipase activity of the dosage form is from about 675 to about 825 USP-units, the protease activity is from 1,250 to 3,850 USP units and the amylase activity from 1,600 to 6,575 USP units. 
Dozna forma u skladu sa zahtjevom 12, naznačena time što je aktivnost lipaze u sadržaju dozne forme od oko 675 do oko 825 USP jedinica, aktivnost proteaze od oko 1 250 do oko 3 850 USP jedinica i aktivnost amilaze od oko 1600 do oko 6 575 USP jedinica.
In one embodiment, provided herein are compounds of Formula II: 
Spoj sukladno zahtjevu 1 s formulom II: U A
A pharmaceutical composition comprising a compound according to claim 4 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema zahtjevu 2 1 farmaceutski prihvatljiv nosač.
A method for preparing a compound of Formula XI, or racemate, or pharmaceutically acceptable salt thereof, comprising the step of reacting Formula II compound with Lawesson's reagent: wherein, in Formulae II and XI, X1, X2, X3, R1, R2, R3, R4, R5, R6, R7, R8 and Y are the same as defined in claim 1. 
predstavlja reaktivnu odlazeću skupinu. Postupak pripreme spoja Formule XI, ili njegovog racemata ili farmaceutski prikladne soli, koji obuhvaća korak reakcije spoja Formule II s Lawessonovim reagensom:
the agent for treatment of diabetes is a biguanide (e.g. metformin), a sulfonylurea, a meglitinide or glinide (e.g. nateglinide), a DPP-IV inhibitor, an SGLT2 inhibitor, a glitazone, a different GLP-1 agonist, an insulin or an insulin analogue; 
sredstvo za liječenje dijabetesa je bigvanid (primjerice metformin), sulfonilurea, meglitinid ili glinid, (primjerice nateglinid), DPP-IV-inhibitor, SGLT2-inhibitor, glitazon, neki drugi agonist za GLP-1, inzulin ili analog inzulina;
A pharmaceutical composition comprising an antibody of any one of claims 1-18 and/or a conjugate of claim 20, and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak koji sadrži protutijelo sukladno patentnom zahtjevu I i/ili konjugat sukladno patentnom zahtjevu 3 i farmaceutski prihvatljiv nosač.
Preferably, said hybridoma produces an antibody that inhibits the binding of an HLA-c allele molecule having a Lys residue at position 80 to a human KIR2DL1 receptor, and the binding of an HLA-C allele molecule having an Asn residue at position 80 to human KIR2DL2/3 receptors. 
Hibridom prema zahtjevu 12, gdje taj hibridom proizvodi protutijelo koje inhibira vezanje HLA-c alel molekule, koja ima Lys ostatak na položaju 80, za humani KIR2DLI receptor, i vezanje HLA-C alel molekule, koja ima Asn ostatak na položaju 80, za humane KIR2DL2/3 receptore.
According to a still preferred aspect, compounds of the invention are selected from the group consisting in: 3-(4-nonylbenzylamino)cyclopentane-1,1-dicarboxylic acid 3-(4-decylbenzylamino)cyclopentane-1,1-dicarboxylic acid 
Prema još uvijek poželjnom aspektu, spojeve prema ovom izumu se bira 1z skupine koju čine: 3-(4-nonilbenzilamino)ciklopentan-1,1-dikarboksilna kiselina 3-(4-docilbenzilamino)ciklopentan-1,1-dikarboksilna kiselina kao i njihovi enantiomeri, dijastereoizomeri, njihove smjese, slobodni oblici i farmaceutski prihvatljive soli, hidrati, te solvati.
The entire length of the article is wrapped in cigarette-type paper 46. 
Cjela dužina proizvoda umotana je u papir 46 cigaretnog tipa.
The reaction was worked up by pouring the reaction solution into a separatory funnel containing 20mL EtOAc and 30mL saturated sodium bicarbonate solution. 
Reakcijska smjesa je bila dorađena izlijevanjem reakcijske otopine u lijevak za odjeljivanje koji je sadržavao 20 mL EtOAc i 30 mL otopine zasićenog natrij bikarbonata.
Suitably the effector molecule is attached in such a way that a lysyl-maleimide group is attached to the cysteine residue at the C-terminal end of the heavy chain, and each amino group of the lysyl residue has covalently linked to it a methoxypoly(ethyleneglycol) residue having a molecular weight of about 20,000 Da. 
Protutijelo prema bilo kojem od zahtjeva 10 do 13, naznačeno time što ima vezano na jedan od cisteinskih ostataka na C-terminalnom kraju teškog lanca protutijela lizil-maleimidne skupine ili lizil bis-maleimidne skupine; pri čemu svaka amino skupina lizilnog ostatka ima na nju kovalentno vezan metoksipoli(etilenglikol) ostatak koji ima molekulsku masu od oko 20,000 Da.
This XO-dependent mechanism of oxygen radical production has been invoked to explain the involvement of O2− and H2O2 in reperfusion injury to a variety of organs, including intestine, brain, heart, and skeletal muscle. 
Taj mehanizam proizvodnje kisikovog radikala, ovisan o XO, uključen je u objašnjenje uključenja O» 1 HO, u reperfuzijsku ozljedu u raznim organima, uključiv crijeva, mozak, srce i mišić kostura.
The HA in living organisms occurs as a salt formed with a cation, usually sodium, and its molecular weight may range from 10-20 kDa to several thousands kDa. 
U živim organizmima HA se pojavljuje kao sol formirana sa kationima, najčešće natrijem, i njegova molekularna težina se može kretati od 10-20 kDa.
The puller assembly of claim 1 wherein said at least one radial inward projection comprise a plurality of axially spaced teeth. 
Sklop ekstraktora prema patentnom zahtjevu 1, naznačen time, što se predmetno najmanje jedno radijalno izbočenje prema unutra sastoji od više aksijalno razmaknutih zubaca (102-106).
This application claims priority of the benefits of the filing of European Patent Convention Application No. 
Broj europske prijave patenta: EP 08708576.7 Datum podnošenja europske prijave patenta:
The method according to claim 1, wherein the xerostomia is associated with Sjogren's syndrome. 
Betanekol za uporabu prema zahtjevu 1, pri čemu je kserostomija povezana sa Sjogrenovim sindromom.
The polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:35 residues 1-378. 
Polipeptid iz patentnog zahtjeva 1, koji sadrži aminokiselinsku sekvencu u skladu sa SEK ID BR:35 ostaci 1-378.
Next was charged 15mg (0.081mmol, 0.1 eq.) 
Nakon toga je bilo stavljeno 15 mg (0.081 mmol, 0.1 ekv.)
represents Lys wherein the -NH2 side chain group is functionalized with a group -Z-C(O)R5, wherein Z represents a group selected from YE, YE-YE, AEEAc-AEEAc-YE and AEEAc-AEEAc-AEEAc and R5 represents a group selected from pentadecanyl, heptadecanyl or 16-carboxy-hexadecanyl . 
predstavlja Lys pri čemu je skupina -NH2 bočnog lanca funkcionalizirana sa skupinom -Z-C(O)R5, pri čemu Z predstavlja skupinu odabranu od YE, YE-YE, AEEAc-AEEAc-YE i AEEAc-AEEAc-AEEAc i predstavlja skupinu odabranu od pentadekanila ili heptadekanila ili 16-karboksi-heksadekanila.
The method of claim 1 or 2 wherein the compound of Formula I is a compound of Formula Ib: or a salt thereof and the compound of Formula II is represented by Formula IIb: or a salt thereof. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da je spoj Formule I spoj Formule Ib: HR P20130862 T1 KL i
the product B consisting of at least one inorganic colloidal binding agent said composition being in a thermoset stage and said heat resistant fibers being glass fibers, silica fibers or a mixture thereof.. 
proizvod B koji sadrži najmanje jedno anorgansko koloidno vezivno sredstvo, navedena vlakna otporna na toplinu su staklena vlakna, silicijska vlakna ili njihova smjesa, i navedeni pripravak je u termoset fazi.
coupling the compound of Formula 62 with an acid or acid chloride under standard amide formation conditions to provide a compound of Formula 63 
kondenziranju spoja Formule 62 s kiselinom ili kiselinskim kloridom u standardnim uvjetima za dobivanje amida kako bi se dobilo spoj Formule 63 [image] .
The method of claim 17, said silane present in an amount of from 0.2% to 1.0% by weight based on the total weight of the binder composition. 
trimetoksisilan ili gamaglicidoksipropiltrimetoksisilan, poželjno u količini od 0.2% do 1.0% težinski temeljeno na ukupnoj težini vezivne smjese.
Pharmaceutical according to any one of claims 5 to 7, characterized in that the active substances are presented in fixed or free combination for simultaneous, sequential or separate administration together with the usual excipients, adjuncts, and additives in a pharmaceutical form suitable for inhalative application. 
Farmaceutski proizvod sukladno bilo kojem od patentnih zahtjeva 5 do 7, naznačen time, da je djelatna tvar nazočna u fiksiranoj ili slobodnoj kombinaciji za istovremeno, povremeno ili odvojeno davanje zajedno s uobičajenim ekscipijensima, adjunktima i aditivima u farmaceutskom obliku prikladnome za inhalatornu primjenu.
In particular, said glycosylated polypeptide expressed in the transformed microalgae comprises a glycosylation pattern suitable for therapeutic purposes. 
Metoda za proizvodnju najmanje jednog glikoziliranog polipeptida koji ima uzorak glikozilacije pogodan za terapijsku svrhu, koja obuhvaća korake:
A compound of a general formula (I): wherein, A1 and A2 each independently mean a nitrogen atom, or mean a methine group optionally substituted with a halogen atom, a hydroxyl group, a cyano group, a C1-C6 alkyl group, a C1-C6 alkoxy group or a hydroxy-C1-C6 alkyl group; 
Tvar opće formule (I) [image] pri čemu i A2 svaki nezavisno predstavlja atom dušika, ili predstavlja metinsku grupu opcionalno supstituiranu s atomom halogena, hidroksilnu grupu, cijano grupu, C1-C6 alkilnu grupu, C1-C6 alkoksi grupu ili hidroksi- C1-C6 alkilnu grupu;
preparing a solution comprising labeled platelet-activating factor (PAF); 
(i) pripravljanje otopine koja sadržava označeni faktor za aktiviranje trombocita (PAF);
The method, use or article of manufacture of item 13, wherein culturing conditions of said three-dimensional culture comprise an adherent material selected from the group consisting of a polyester and a polypropylene. 
Stanice ili proizvodni artikl, namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 5 1 7 do 10, naznačeni time što uvjeti uzgoja u navedenoj trodimenzionalnoj kulturi uključuju adherentni materijal, koji se bira iz skupine koju čine poliester i polipropilen.
A method of treating a patient in need thereof comprising the step of administering a therapeutically effective amount of an antibody molecule comprising a serum albumin antibody or antigen-binding fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 and a light chain variable domain having the sequence given in SEQ ID NO: 3. 
Protutijelo koje veže serumski albumin ili njegov fragment naznačeno time da sadrži varijabilnu domenu teškog lanca koja ima sekvencu navedenu u SEQ ID NO: 1 i varijabilnu domenu lakog lanca koja ima sekvencu navedenu u SEQ ID NO:3.
The composition of Claim 3 wherein the component (b) is flonicamid and the weight radio of the component (b) to the compound of Formula 1, an N -oxide, or salt thereof, is from 20:1 to 1:500, preferably from 15:1 to 1:250, and more preferably from 5:1 to 1:50. 
Metoda iz patentnog zahtjeva 1 gdje omjer mase abamektina i tvari iz Formule 1 iznosi 50:1 do 1:500, poželjno 25:1 do 1:250, još poželjnije 5:1 do 1:100.
The immunoconjugate of claim 5, wherein said amino acid mutation is an amino acid substitution at position P329 (EU numbering). 
Imunokonjugat prema zahtjevu 5, naznačen time, da navedena aminokiselinska mutacija je aminokiselinska supstitucija na položaju P329 (EU numeracija).
The process according to claim 18, wherein, in depositing step e), said melted chocolate is dispensed through a dispenser nozzle, comprising at least two holes suitably spaced from each other, and deposited in the form of two strips onto the upper surface of the lower portion of the bakery product, said strips undergoing widening sufficient for them to come into contact with one another to create a continuous chocolate layer, but not to cause spilling of the chocolate beyond the edges of the deposition surface. 
Postupak prema patentnom zahtjevu 19, naznačen time što, u navedenom koraku e) nanošenja, navedena otopljena čokolada se raspodjeljuje kroz mlaznicu za doziranje, koja sadrži najmanje dvije rupe prikladno razmaknute jedna od druge, i nanosi se u obliku dvije trake na gornju površinu donjeg dijela pekarskog proizvoda, navedene trake se proširuju dovoljno da dođu u kontakt jedna s drugom da bi stvorile kontinuirani sloj čokolade, ali da ne dovedu do prelijevanja čokolade preko rubova površine na koju je nanesena.
The compound according to claim 1, wherein: 
Spoj 1z zahtjeva 1, pri čemu je spoj:
A compound of Formula I-E: wherein A, B, C, and D are independently selected from CR1 and N; wherein at least one of A, B, C, and D is CR1; wherein R1 is selected from H, alkyl, heteroalkyl, aryl, arylalkyl, halogen; and wherein when two adjacent of A, B, C, and D are CR1, the two R1's may combine to form a single aryl, cycloalkyl, or heterocycloalkyl group; 
O O gdje su A, B, C 1 D nezavisno izabrani od CR, i N; gdje je najmanje jedan od A, B, Ci D jednak CR;; gdje je R; izabran od H, alkil, heteroalkil, aril, arilalkil, halogen grupe; i gdje kada su dva susjedna od A, B, CiD jednaka CR;, dva R; mogu se spojiti tako da formiraju jednu aril, cikloalkil ili heterocikloalkil grupu;
the delay of reactivation of tuberculosis. 
(e) -odgađanju reaktiviranja tuberkuloze.
said element has a desired shape obtained as the result of a thermoforming operation. 
– navedeni element ima željeni oblik, dobiven postupkom termoformiranja.
In a sixth class of this embodiment, substantially all of the dihydrogenphosphate salt drug substance is the crystalline monohydrate of the present invention, i.e., the dihydrogenphosphate salt drug substance is substantially phase pure monohydrate. 
U šestoj klasi ove implementacije, gotovo cijela supstanca lijeka dihidrogenfosfatne soli je kristalni monohidrat predmetnog izuma, tj. supstanca lijeka dihidrogenfosfatne soli je uglavnom fazno čisti monohidrat.
To a solution of intermediate 42 (660 mg, 2.6 mmol) in THF (10 mL) and water (2 mL) was added triphenylphosphine (740 mg, 2.8 mmol), and the mixture stirred under nitrogen for 1 h. 
U otopinu Intermedijera 42 (660 mg, 2.6 mmol) u THF (10 mL) i vodi (2 mL) dodan je trifenilfosfin (740 mg, 2.8 mmol), i smjesa je miješana pod dušikom 1 sat.
and the enantiomers, diastereomers, salts, solvates or salts of solvates thereof. 
i njihovi enantiomeri, diastereomeri, soli, solvati ili soli solvata.